Please provide your email address to receive an email when new articles are posted on . This combined procedure provides the benefit of improving vision and decreasing IOP postoperatively, which can ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Contraindications: The iStent inject W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior ...

Optometrist Dr. David Kordish often talks to patients about glaucoma and cataracts in doing general eye care. Now, he can see his patients with clearer vision and freedom from glaucoma medication ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

Glaukos Corp. (NYSE: GKOS) is seeing its continued efforts to bring new and improved products to the micro-invasive glaucoma surgery (MIGS) market pay off. MIGS-related net sales for the San Clemente ...

Glaukos Corporation GKOS is well-poised for growth backed by strength in iStent technology and robust product portfolio. However, stiff competition remains a concern. Shares of this Zacks Rank #3 ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted 510(k) clearance for the iStent infinite trabecular micro-bypass system to reduce IOP as a stand ...

Needham expects Glaukos Corp (NYSE:GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside ...